Short answer
Coherus Oncology, Inc. (CHRS) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $14M (up 39.5% year over year) with net income of −$21M.
Q2 2026 key financials · XBRL
- Revenue
- $14M
- +39.5% YoY · +16.2% QoQ
- Net income
- −$21M
- −106.9% YoY · +46.2% QoQ
- Operating margin
- -226.0%
- EPS (diluted)
- −$0.12
- −104.7% YoY · +57.1% QoQ
Source: XBRL data from the Coherus Oncology, Inc. (CHRS) Q2 2026 10-Q on SEC EDGAR. USD.
Coherus Oncology, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $14.3M, up $4.1M YoY from $10.3M, driven by LOQTORZI volume growth
- LOQTORZI revenue $13.6M, up $3.7M YoY from $10.0M
- Gross margin 70% vs 67% YoY, with cost of goods sold $4.2M vs $3.4M
- Cash, equivalents and marketable securities $105.3M vs $172.1M at December 31, 2025
- 2026 outlook: higher net revenue, lower R&D and SG&A expenses, comparable interest expense
Risk Factors
- UDENYCA Sale completed, increasing profitability risk as LOQTORZI replaces the divested product’s larger revenue contribution
- Cash, cash equivalents and marketable securities $105.3 million as of June 30, 2026, with continued dependence on additional funding
- LOQTORZI competition from chemotherapy and off-label immunotherapy agents in nasopharyngeal carcinoma
- Regulatory noncompliance exposure, including potential product recalls, approval withdrawal, civil or criminal penalties
- LOQTORZI license obligations include up to $90.0 million in regulatory milestones and $290.0 million in sales-threshold payments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Coherus Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.